# Aurion Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aurion-biotechnologies

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.aurionbiotech.com
- Total disclosed funding: $55M
- Latest round: Series C (Apr 5, 2022)
- Investors on record: 6

## About

Based in Washington, US, and founded in 2022, Aurion Biotechnologies, also known as Aurion Biotech, offers regenerative therapies to cure blindness. In April 2022, Aurion Biotechnologies raised USD 55.30 million in venture funding led by new investor Deerfield Management, with participation from another new investor Alcon Labs, Inc. Returning investors Falcon Vision, Flying L Partners, etc. As of May 2022, the firm operates from Seattle, Washington, Cambridge, Massachusetts, and Tokyo, and Greg Kunst is the CEO. The company provides cell therapy for corneal endothelial disease using its proprietary technology Vyznova ™ which cultures healthy cells from a donor’s cornea and manufactures treatments for more than a hundred recipient eyes at a faster rate and with less eye invasion. Aurion Biotechnologies' intends to use its April 2022 funding in its next phase of growth and innovation.

## Funding rounds

- Series C, Apr 5, 2022, $55M — Alcon Switzerland SA, Deerfield Management, Visionary Venture Fund, Flying L Partners, Petrichor, Falcon Vision

## Investors

- Alcon Switzerland SA — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C
- Visionary Venture Fund (https://capitalatlas.ai/funds/visionary-venture-fund) — Series C
- Flying L Partners (https://capitalatlas.ai/funds/flying-l-partners) — Series C
- Petrichor (https://capitalatlas.ai/funds/petrichor) — Series C
- Falcon Vision — Series C